Following Its Recent Approval in the United States and Europe for Osteoporosis, Prolia Will Garner Sales of More than $500 Million in 2019
Advertisement
Prolia's Uptake Will Be Constrained by Its Premium Price and the Increasing Availability of Generic Drugs, According to Findings from Decision Resources